Table 4 Treatment measures, complications, and clinical outcomes
| Â | Total | Active CMV infection | P | |
|---|---|---|---|---|
N = 87 | Yes (n = 14, 16.1%) | No (n = 73, 83.9%) | ||
Treatment measures, n (%) | ||||
 Before ICU admission | ||||
  Glucocorticoids | 32 (36.8) | 6 (42.9) | 26 (35.6) | 0.607 |
  Immunosuppressive drugs^ | 12 (13.8) | 2 (14.3) | 10 (13.7) | > 0.999 |
  Gamma globulin infusions | 10 (11.5) | 0 (0) | 10 (13.7) | 0.310 |
  Blood transfusiona | 13 (15.0) | 5 (35.7) | 8 (11.0) | 0.049 |
 After ICU admission | ||||
  Glucocorticoids | 25 (28.7) | 3 (21.4) | 22 (30.1) | 0.736 |
  Immunosuppressive drugs^ | 4 (4.6) | 1 (7.1) | 3 (4.1) | 0.511 |
  Gamma globulin infusions | 19 (21.8) | 4 (28.6) | 15 (20.6) | 0.755 |
  Blood transfusion | 38 (43.7) | 8 (57.1) | 30 (41.1) | 0.267 |
 Antiviral therapy#a | 14 (16.1) | 14 (100) | 0 (0) | < 0.001 |
  CRRT | 34 (39.1) | 7 (50.0) | 27 (37.0) | 0.361 |
  ECMO | 13 (14.9) | 2 (14.3) | 11 (15.1) | > 0.999 |
Complications, n (%) | ||||
 Septic shocka | 56 (64.4) | 13 (92.9) | 43 (58.9) | 0.034 |
  AKI | 44 (50.6) | 10 (71.4) | 34 (46.6) | 0.088 |
  DIC | 24 (27.6) | 6 (42.9) | 18 (24.7) | 0.285 |
  AHF | 16 (18.4) | 5 (35.7) | 11 (15.1) | 0.147 |
  AECOPD | 13 (14.9) | 2 (14.3) | 11 (15.1) | > 0.999 |
 Clinical outcomes | ||||
  28-day VFD (d) | 0 (0–13) | 0 (0–0) | 0 (0–14) | 0.134 |
  Length of IMV | 27 (13–55) | 40 (26–82) | 24 (13–51) | 0.072 |
 Duration of ICU staya (d) | 30 (15–57) | 51 (26–104) | 29 (15–57) | 0.035 |
  Duration of hospital stay (d) | 39 (26–85) | 56 (32–127) | 39 (26–80) | 0.330 |
  In-hospital mortality, n (%) | 8 (9.2) | 2 (14.3) | 6 (8.2) | 0.830 |